What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2353.png

 

Jakavi MF

 

“Extend your MF patients’ survival with JAKAVI at diagnosis1”

 

Myelofibrosis (MF)

Jakavi is indicated for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis2

Group 2354.png
Frame 427318873.png
Overall Survival
Frame 427318874.png
Symptoms Control
Frame 427318875.png
Spleen Reduction
Frame 427318860.png
Dosing

For JAKAVI-MF Abbreviated prescribing information

PDF
View

References

  1. Verstovsek S, Gupta V, Gotlib JR, et al. A pooled overall survival (OS) analysis of 5-year data fr om the COMFORT-I and COMFORT-II trials of ruxolitinib for the treatment of myelofibrosis (MF). Blood. 2016;128(22):3110 

  2. Egyptian drug authority(EDA). Jakavi Approved Leaflet approval date 18-03-2024 

  3. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707. 

  4. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, The Journal of the American Society of Hematology. 
    2012 Aug 9;120(6):1202-9 

Approved by Egyptian Drug Authority: HF0424OA4703/102025. Invalidation date: 17/12/2025.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg.

Jakavi QR

HF0424OA4703/102025 17/12/2025